Approval · Notice of Compliance 2825 · 1998
CAELYX: Notice of Compliance 2825
Issued July 20, 1998
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2825
- Date
- July 20, 1998
- Company
- Schering Canada Inc.
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Priority
- Therapeutic class
- Antineoplastic agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CAELYX | 02238389 | Marketed |
Medicinal ingredients
- DOXORUBICIN HYDROCHLORIDE 2 MG per ML